MetaCap

Neuropace (NPCE) vs SS Innovations International (SSII)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Neuropace (NPCE) has outperformed SS Innovations International (SSII) over the past year, losing 44.6% versus a loss of 78.7%. Neuropace is the larger company by market cap ($273.9 million vs $254.9 million), about 1.1 times the size, while SS Innovations International is growing revenue faster (+105.7% vs +25.1%). Neuropace converts more of its revenue into profit, with a net margin of -21.5% versus -28.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NPCE-44.60%SSII-78.69%
+40%-22%-84%
Nov 21, 20251 yearNov 20, 2026
NPCE+13.90%SSII-66.13%
+217%+56%-106%
Aug 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NPCE versus SSII key metrics
MetricNPCESSII
Share price$7.95$1.27
Market cap$273.89M$254.86M
1-day change-2.33%-0.78%
YTD return-48.51%-77.64%
1-year return-44.60%-78.69%
5-year return-32.80%—
EPS (TTM)$-0.56$-0.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$99.99M$42.48M
Revenue growth (YoY)+25.13%+105.74%
Net income (latest FY)$-21.46M$-12.13M
Gross margin77.23%46.00%
Operating margin-16.34%-19.29%
Net margin-21.47%-28.55%
52-week high$19.60$6.79
52-week low$5.46$1.12
Distance from 52-week high-59.44%-81.30%
Analyst consensusbuynone
Avg. price target upside+53.71%+451.18%
Average volume270.76K86.18K
Shares outstanding34.45M200.68M
Employees216483
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NPCE has outperformed SSII by 34.1 percentage points over the past year.
  • Neuropace is more profitable, keeping -21.5 cents of every revenue dollar as net income versus -28.5 cents for SS Innovations International.
  • SS Innovations International grew revenue faster in its latest fiscal year (+105.74% vs +25.13%).

About Neuropace

NPCE stock →

NeuroPace, Inc. operates as a medical device company in the United States.

Health Care · Medical/Dental Instruments · 216 employees

About SS Innovations International

SSII stock →

SS Innovations International, Inc., together with its subsidiaries, operates as a commercial-stage surgical robotics company in India, Philippines, Indonesia, South America, Iraq, Cyprus, Oman, United Arab Emirates (UAE), Nepal, and internationally. It offers SSi Mantra, a surgical robotic system; and SSi Mudra, a range of stapling, energy, and core instrumentations for surgical systems.

Health Care · Medical/Dental Instruments · 483 employees

NPCE vs SSII FAQ

Which is bigger, Neuropace or SS Innovations International?

Neuropace (NPCE) is larger, with a market capitalization of $273.89M compared with $254.86M for SS Innovations International (SSII).

Which stock has performed better over the past year, NPCE or SSII?

NPCE returned -44.60% over the past 12 months, compared with -78.69% for SSII (price return, excluding dividends). Past performance does not predict future results.

Are Neuropace and SS Innovations International in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons